Trendlines Group, Ltd.  (OTC: TRNLY) Delivering 10X returns on Israeli medical and agricultural innovation

Steve Rhodes, co-CEO, Trendlines.



Steve Rhodes






Trendlines Group, Ltd.  (OTC: TRNLY) (Singapore: 42T), interview with co-CEO/Chairman Steve Rhodes, discussing the company’s investment strategy in early-stage medical and agricultural innovation companies in Israel and Singapore. Since 2011, Trendlines’ successful strategy, of hands-on investment has yielded over a 10X return, and a 95% IRR on 8 exits to date.

The company currently has 51 companies in it’s portfolio with a carry value of about $100 million. (This may be a conservative estimate as it’s exits have yielded returns which were 3-4X carried value estimates. Trendlines investment in it’s most recent successful exit, Stimatix, is valued at about $40 million (which is less than Trendlines’ total market cap as of 12/24/18). 

In this interview, Steve Rhodes explains the company’s investment methodology, highlights a few advanced stage portfolio companies in medical and agriculture, and shares what’s ahead for 2019.  

Investor Presentation

Trendlines progress since IPO – Nov 2018
Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.